Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • Validive
      • Overview
      • Severe Oral Mucositis and Oropharyngeal Cancer
      • Phase 2 Data Supports Further Development in OPC
      • MNPR-301-001 Clinical Trial
    • Camsirubicin
      • Overview
      • Clinical Data
      • Development Strategy
      • MNPR-201-001 Clinical Trial
    • MNPR-101 RIT
    • MNPR-101
      • Overview
      • Development Strategy
    • MNPR-202
    • Collaborations
      • Overview
      • Current Collaborations
    • Intellectual Property
    • Publications
      • Validive
      • Camsirubicin
      • MNPR-101
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Contact Us Contact Us
  • SIV Materials SIV Materials
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates

Aug 6, 2020

Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR

Jun 30, 2020

Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19

Jun 16, 2020

Monopar Therapeutics Reports First Quarter 2020 Financial Results and Business Updates

May 7, 2020

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates

Mar 27, 2020

Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma

Feb 18, 2020

Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock

Dec 23, 2019

Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters

Dec 20, 2019

Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering

Dec 18, 2019

Monopar Therapeutics and the Spanish Sarcoma Group (GEIS) Team Up on Phase 2 Sarcoma Trial With Monopar's Novel Camsirubicin

Jul 2, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • About
    • Pipeline
    • Investors
    • Our Team
    • Contact Us
    • SIV Materials
    • Pipeline
    • Pipeline Chart
    • Validive
    • Camsirubicin
    • MNPR-101 RIT
    • MNPR-101
    • MNPR-202
    • Collaborations
    • Intellectual Property
    • Publications
    • Investors
    • Overview
    • Annual Meeting
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance

    Terms and Conditions of Use

    © 2023 Monopar Therapeutics Inc. All Rights Reserved.